Senti Biosciences (SNTI) Projected to Post Earnings on Thursday

Senti Biosciences (NASDAQ:SNTI) is projected to announce its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect the company to announce earnings of ($0.43) per share and revenue of $1.00 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 27, 2026 at 4:00 PM ET.

Senti Biosciences Trading Up 5.4%

Senti Biosciences stock opened at $0.98 on Tuesday. The company has a market cap of $25.80 million, a P/E ratio of -0.29 and a beta of 2.12. Senti Biosciences has a 1-year low of $0.80 and a 1-year high of $5.10. The company has a fifty day simple moving average of $0.98 and a 200 day simple moving average of $1.41.

Institutional Investors Weigh In On Senti Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of SNTI. Armistice Capital LLC acquired a new stake in Senti Biosciences in the 2nd quarter valued at about $1,883,000. Geode Capital Management LLC increased its position in Senti Biosciences by 395.6% during the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after buying an additional 117,588 shares during the last quarter. Citadel Advisors LLC acquired a new position in Senti Biosciences during the third quarter worth approximately $117,000. Virtu Financial LLC acquired a new position in Senti Biosciences during the fourth quarter worth approximately $46,000. Finally, Jane Street Group LLC bought a new stake in Senti Biosciences in the fourth quarter valued at approximately $40,000. 25.70% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on SNTI. Weiss Ratings restated a “sell (e+)” rating on shares of Senti Biosciences in a research note on Thursday, January 22nd. Chardan Capital lifted their target price on Senti Biosciences from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Wall Street Zen upgraded Senti Biosciences to a “sell” rating in a report on Saturday, December 13th. Finally, Leerink Partners assumed coverage on Senti Biosciences in a research report on Friday, November 21st. They set an “outperform” rating and a $6.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $9.00.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.